ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 43 filers reported holding ONCOMED PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $231,000 | -0.9% | 108,943 | +8.2% | 0.00% | 0.0% |
| Q2 2018 | $233,000 | +17.1% | 100,691 | +60.8% | 0.00% | 0.0% |
| Q1 2018 | $199,000 | -19.8% | 62,600 | +3.5% | 0.00% | 0.0% |
| Q4 2017 | $248,000 | -21.5% | 60,475 | -13.5% | 0.00% | -50.0% |
| Q3 2017 | $316,000 | +35.6% | 69,900 | -0.3% | 0.00% | 0.0% |
| Q2 2017 | $233,000 | – | 70,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,108,815 | $4,273,000 | 0.48% |
| Birchview Capital, LP | 372,557 | $387,000 | 0.24% |
| Perceptive Advisors | 1,719,111 | $1,787,000 | 0.05% |
| Fondren Management LP | 25,136 | $26,000 | 0.02% |
| Cannell & Co. | 281,983 | $293,000 | 0.01% |
| APPLETON PARTNERS INC/MA | 66,206 | $69,000 | 0.01% |
| Quinn Opportunity Partners LLC | 66,162 | $69,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 38,000 | $40,000 | 0.01% |
| Candriam S.C.A. | 380,000 | $395,000 | 0.01% |
| PRIMECAP MANAGEMENT CO/CA/ | 5,451,400 | $5,669,000 | 0.00% |